MX2023010728A - Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. - Google Patents

Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.

Info

Publication number
MX2023010728A
MX2023010728A MX2023010728A MX2023010728A MX2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A
Authority
MX
Mexico
Prior art keywords
depressive disorder
major depressive
subject
disubstituted
treatment
Prior art date
Application number
MX2023010728A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Jay Kanes
James Doherty
Handan Gunduz-Bruce
Robert Alfonso Lasser
Jeffrey Martin Jonas
Joi Lisa Dunbar
Bambang Senoaji Adiwijaya
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023010728A publication Critical patent/MX2023010728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023010728A 2021-03-17 2022-03-17 Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. MX2023010728A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162501P 2021-03-17 2021-03-17
US202163284592P 2021-11-30 2021-11-30
PCT/US2022/020716 WO2022197901A1 (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Publications (1)

Publication Number Publication Date
MX2023010728A true MX2023010728A (es) 2024-02-12

Family

ID=81327141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010728A MX2023010728A (es) 2021-03-17 2022-03-17 Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.

Country Status (11)

Country Link
US (1) US20240245711A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308162A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510436A (cg-RX-API-DMAC7.html)
KR (1) KR20230158033A (cg-RX-API-DMAC7.html)
AU (1) AU2022238365A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018607A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213744A1 (cg-RX-API-DMAC7.html)
IL (1) IL305858A (cg-RX-API-DMAC7.html)
MX (1) MX2023010728A (cg-RX-API-DMAC7.html)
TW (1) TW202300156A (cg-RX-API-DMAC7.html)
WO (1) WO2022197901A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders

Also Published As

Publication number Publication date
TW202300156A (zh) 2023-01-01
JP2024510436A (ja) 2024-03-07
US20240245711A1 (en) 2024-07-25
WO2022197901A1 (en) 2022-09-22
KR20230158033A (ko) 2023-11-17
EP4308162A1 (en) 2024-01-24
CA3213744A1 (en) 2022-09-22
IL305858A (en) 2023-11-01
BR112023018607A2 (pt) 2023-10-24
AU2022238365A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
BR112023018607A2 (pt) Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
BR112021018627A2 (pt) Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
WO2020205473A8 (en) Compositions and methods for the treatment of kras associated diseases or disorders
ZA202104678B (en) Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
JP2021535161A5 (cg-RX-API-DMAC7.html)
MX2024014467A (es) Métodos de tratamiento del cáncer con un inhibidor de mtor
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
WO2020132560A3 (en) Compositions and methods for cancer therapy
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
JP2022546456A5 (cg-RX-API-DMAC7.html)
MX2024003650A (es) Metodos de dosificacion de inhibidores de transportador apical de acidos biliares dependiente de sodio (asbtis).
WO2023205481A9 (en) Bavdegalutamide and combinations thereof for use in treating prostate cancer
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2023005027A (es) Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.
PH12022553376A1 (en) Acalabrutinib maleate dosage forms
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2023009620A (es) Metodos terapeuticos.
MX2024001266A (es) 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
MX2022006071A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa.